Isolation, Expansion and Characterization of Bone Marrow-derived Mesenchymal Stromal Cells in Serum-free Conditions
Overview
Cell Biology
Authors
Affiliations
Bone marrow-derived mesenchymal stromal cells (BM-MSCs) heralded a new beginning for regenerative medicine and generated tremendous interest as the most promising source for therapeutic application. Most cell therapies require stringent regulatory compliance and prefer the use of serum-free media (SFM) or xeno-free media (XFM) for the MSC production process, starting from the isolation onwards. Here, we report on serum-free isolation and expansion of MSCs and compare them with cells grown in conventional fetal bovine serum (FBS)-containing media as a control. The isolation, proliferation and morphology analysis demonstrated significant differences between MSCs cultured in various SFM/XFM in addition to their difference with FBS controls. BD Mosaic™ Mesenchymal Stem Cell Serum-Free media (BD-SFM) and Mesencult-XF (MSX) supported the isolation, sequential passaging, tri-lineage differentiation potential and acceptable surface marker expression profile of BM-MSCs. Further, MSCs cultured in SFM showed higher immune suppression and hypo-immunogenicity properties, making them an ideal candidate for allogeneic cell therapy. Although cells cultured in control media have a significantly higher proliferation rate, BM-MSCs cultured in BD-SFM or MSX media are the preferred choice to meet regulatory requirements as they do not contain bovine serum. While BM-MSCs cultured in BD-SFM and MSX media adhered to all MSC characteristics, in the case of few parameters, the performance of cells cultured in BD-SFM was superior to that of MSX media. Pre-clinical safety and efficiency studies are required before qualifying SFM or XFM media-derived MSCs for therapeutic applications.
Spoerer T, Larey A, Asigri W, Daga K, Marklein R Stem Cell Res Ther. 2025; 16(1):125.
PMID: 40055728 PMC: 11889916. DOI: 10.1186/s13287-025-04206-8.
Animal origins free products in cell culture media: a new frontier.
Golshan M, Dortaj H, Rajabi M, Omidi Z, Golshan M, Pourentezari M Cytotechnology. 2024; 77(1):12.
PMID: 39654546 PMC: 11625046. DOI: 10.1007/s10616-024-00666-7.
Kang M, Yang Y, Zhang H, Zhang Y, Wu Y, Denslin V Int J Mol Sci. 2024; 25(19).
PMID: 39408956 PMC: 11476526. DOI: 10.3390/ijms251910627.
Clinical and preclinical studies of mesenchymal stem cells to alleviate peritoneal fibrosis.
Zheng L, Chen W, Yao K, Xie Y, Liao C, Zhou T Stem Cell Res Ther. 2024; 15(1):237.
PMID: 39080683 PMC: 11290310. DOI: 10.1186/s13287-024-03849-3.
Mazzella M, Walker K, Cormier C, Kapanowski M, Ishmakej A, Saifee A Stem Cell Res Ther. 2023; 14(1):305.
PMID: 37880755 PMC: 10601332. DOI: 10.1186/s13287-023-03533-y.